NCT02961101 2026-01-22
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Chinese PLA General Hospital
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT05662397 2025-02-04
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
HotSpot Therapeutics, Inc
Phase 1/2 Active not recruiting
NCT05631886 2023-08-28
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
Phase 1 Recruiting
NCT02605967 2022-02-10
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Novartis
Phase 2 Completed
NCT04778956 2021-03-04
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT03914352 2019-04-16
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Cancer Hospital of Guangxi Medical University
Phase NA Unknown